Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
BRITAIN's annual inflation rate fell to a three-year low in September, official data showed Wednesday (16), fuelling speculation that the Bank of England will resume cutting interest rates next month.
The Consumer Prices Index (CPI) reached 1.7 per cent last month, well below the BoE's two-per cent target, after hitting 2.2 per cent in August, the Office for National Statistics (ONS) said in a statement.
The inflation rate was lower than the 1.9 per cent rise that analysts forecast and has cemented expectations that the central bank would likely cut interest rates again in November.
"Lower airfares and petrol prices were the biggest driver of this month's fall," said Grant Fitzner, chief economist at the ONS.
He added that this was partially offset by a strengthening in food price inflation for the first time since early last year.
The inflation data "clears the path for another 25-basis point rate cut in November", said Richard Flax, chief investment officer at wealth management company Moneyfarm.
"The underlying conditions support this move -– energy prices have eased, the economy has cooled, and the labour market has stabilised," he said.
Chancellor Rachel Reeves (C) chairs a meeting of the National Wealth Fund Taskforce at 11 Downing Street on July 9, 2024 in London, England. (Photo by Justin Tallis - WPA Pool/Getty Images)
It comes after official data on Tuesday (15) showed an easing in Britain's unemployment rate and wage growth, which also bolstered analysts expectations of a rate cut.
"It is absolutely amazing to see such a dramatic drop in the UK's CPI number, and the news had brought nothing (but) good things for the Bank of England," said Naeem Aslam, chief investment officer at Zaye Capital Markets.
The inflation news will likely be a boost to the new Labour government ahead of its maiden budget later this month.
Prime minister Keir Starmer has warned Britons that the budget announcement will be "painful", with tax rises and spending cuts expected.
"We are being repeatedly told tough decisions are to be announced, so any sliver of good economic news will likely be pounced upon," said Lindsay James, investment analyst at Quilter Investors.
Starmer's Labour government won power at the start of July, ending 14 years of Tory rule.
In August, the BoE reduced it key rate for the first time since early 2020, from a 16-year high of 5.25 per cent as inflation returned to normal levels.
But it decided against a second reduction in a row in September.
The BoE hiked borrowing costs 14 times between late 2021 -- when they stood at a record-low 0.1 per cent -- and the second half of last year.
Supply-chain disruptions following Covid lockdowns, together with soaring food and energy prices caused by Russia's invasion of Ukraine, sent global inflation surging.
Britain's finance ministry welcomed the fall in inflation, which offers a helpful backdrop for chancellor Rachel Reeves as she readies her first budget, due on Oct. 30.
A less inflationary outlook would slightly improve the economic and fiscal outlook for the budget as Reeves struggles to find the extra money to invest in public services and new infrastructure without spooking investors.
Her spending plans will be watched closely by the BoE.
"Though the stars are aligning for a November rate cut, the upcoming Budget is the final hurdle as rate setters will want to assess the inflationary impact of any measures announced before loosening policy again," Suren Thiru, economics director at ICAEW, an accountancy body, said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.